Actively Recruiting
Study of Blood Thinner Treatment for Portal Vein Clots in Patients with Liver Cirrhosis With or Without Liver Cancer
Led by Mansoura University · Updated on 2025-08-20
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the use of anticoagulant medications in patients with portal vein thrombosis who also have cirrhosis, with or without hepatocellular carcinoma HCC. This phase 4 study aims to assess the effectiveness and safety of anticoagulant therapy in this group, focusing on how these treatments affect portal vein thrombosis over time. Participants will be assigned to one of three groups those with HCC receiving anticoagulants such as Enoxaparin, Warfarin, or Apixaban cirrhotic patients with benign thrombus on similar anticoagulants and cirrhotic patients with thrombosis who are not receiving anticoagulant therapy. The study monitors these groups to compare outcomes related to their treatment status. Throughout the six-month study period, researchers will closely monitor portal vein thrombosis and evaluate the impact of anticoagulant therapy. Participants will undergo regular assessments to track their condition and any potential side effects. The study will collect data on the safety and performance of these medications in managing thrombosis within this patient population.
CONDITIONS
Brief Title
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Research Team
D
Dalia Elsayed Ganady, MBBS
H
Hatem Elalfy, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
